Oncogenic BRAF mutations lead to constitutive activation of the MAPK/ERK pathway, resulting in uncontrolled proliferation, survival, invasiveness, and drug resistance of tumor cells (21, 22). The gene discussed is BRAF; the disease is neoplasm.